Elan reports fall in net losses in 2008 on rise in MS drug Tysabri sales by 140%
Feb 10th, 2009 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Irish pharmaceutical company Elan today reported an 82% fall in net losses for the year ending December 31, 2008. It reported a net loss of $71m for 2008, compared to a loss of $405m reported the previous year, as a result of an improved operating performance. Sales of the MS drug Tysabri jumped 140%.